Stenabolic, also known as SR9009, is a chemical that is used in research. The usage of SR9009 in humans has not been the subject of any published research as of yet.
As a result, we are unable to assess the level of risk posed by this chemical. It is also uncertain whether or not it is effective in people. This indicates that it has a high risk of causing injury and should be avoided under any circumstances.
Our bodies operate in a synchronised manner, according to cycles of twenty-four hours that are calibrated to the rising and setting of the sun. The pattern in question is referred to as the circadian rhythm.
The circadian rhythm is preserved through a feedback loop that alternately activates and deactivates genes (for example, the CLOCK and BMAL1 genes, when activated, also activate the PER and CRY genes). After that, PER/CRY will switch off BMAL1/CLOCK, at which point the 24-hour cycle will begin again) .
There is a pair of proteins known as REV-ERBs, and they are responsible for stabilising our internal clock by inhibiting BMAL1. They, in turn, become active as a result of the heme group. Heme is a tiny iron-containing substance that may be found all throughout our body, including in our red blood cells [1, 2].
SR9009 is a chemical that has high bioavailability and is recognised as an agonist for REV-ERB; it also increases the activity of REV-ERB. 
SR9009 has made its way online, where it is now being marketed and utilised as a supplement, mostly within the bodybuilding community. This is because of the numerous benefits that were shown in animals. The phrase “workout in a bottle” has been used to allude to it. On the other hand, there are many aspects of this medication, such as its adverse effects, that we do not yet fully understand.
The activation of REV-ERB (NR1D1, NR1D2) in the body is the source of all of SR9009’s effects, which have been seen.
The circadian rhythms of mice are disrupted when exposed to REV-ERB, which causes changes in both their activity and sleep habits.
In addition to the effect that it has on the circadian rhythm, which is the inhibition of the synthesis of BMAL1, REV-ERB also has an influence on many other processes that are connected to the generation of energy.
The liver, skeletal muscle, and adipose tissue are the primary locations of REV-ERB.
Mice that were injected with SR9009 for a week saw a reduction in fat mass, which led to a loss of weight. There was no change in the amount of food consumed.
In a similar manner, diet-induced obese mice that were given SR9009 injections over a period of thirty days were able to lose sixty percent more weight than control animals. The levels of insulin, free fatty acids, total cholesterol, and triglycerides in the blood all dropped.
After a period of 12 days, administration of SR9009 prevented further weight gain in genetically obese mice without influencing glucose levels or insulin tolerance.
SR9009 was administered to mice for 7 to 10 days in order to lower their blood levels of triglycerides and total cholesterol.
In order to produce a fat profile comparable to that of people, genetically engineered mice were fed a diet rich in cholesterol for eight weeks prior to receiving SR9009 treatment. There was a reduction in both total cholesterol and triglycerides, a reduction in LDL cholesterol, but no change in HDL cholesterol.
Mice that were given SR9009 over a period of one month exhibited greater endurance. They ran for a greater total amount of time and travelled a farther total distance than the controls.
By inhibiting autophagy genes, SR9009 was able to increase the amount of total mitochondria as well as active mitochondria in muscle cells.
The production of TNF-alpha was decreased in rats treated with SR9009, which resulted in decreased lung inflammation .
Additionally, it was found to be effective in inhibiting the production of inflammatory molecules (CCL2 and MMP-9) in rat nerve cells.
Seven weeks of treatment with SR9009 was administered to genetically engineered mice that were predisposed to developing atherosclerosis. There was a reduction in the size of the blood vessel lesions, but there was no change in the amount of food consumed, body weight, or levels of blood fat.
When administered intraperitoneally for 28 days, SR9009 enhanced the cardiac function of both normal and genetically engineered aged mice.
In mice with surgically induced heart growth (hypertrophy), administration of SR9009 for two weeks resulted in a reduction in both the size and weight of the heart, but had no impact on the animals’ blood pressure.
S9009, which is an activator of REV-ERB, alters the sleeping and waking rhythms of mice. However, its benefits are relatively temporary and only continue for a period of twelve hours.
Mice that were given injections of SR9009 during the daytime, when they are meant to be sleeping, had more activity during the day and experienced less deep sleep than control mice (less REM and slow-wave sleep). However, administration of SR9009 at night (the time of day when mice are most active) resulted in no noticeable changes.
When there is a considerable need to sleep, such as during shift work, jet lag, or some sleep-related problems, SR9009 may have the ability to assist in staying awake.
When given as injections twice daily for 3 to 10 days, SR9009 was found to be equally effective as benzodiazepines in reducing anxiety-like behaviour in rats.
When given to mice with induced liver scarring, SR9009 treatment for two weeks lowered the amount of tissue damage that had occurred.
It is not known whether SR9009 has any adverse effects. The risk for injury caused by this medicine is significant. Because the safety profile of this activity has not been researched, participating in it would be very risky.
When administered to mice for up to seven weeks, SR9009 did not have any harmful effects on the liver.
Several customers complained of experiencing sleeplessness.
There is currently no human dose that has been determined. In the majority of studies, mice were given a dosage of 100 mg/kg that was administered intraperitoneally; this means that the substance was injected directly into the body cavity.
On the other hand, several online bodybuilding communities recommend a far lower daily dose of 10-40 mg. They also recommend separating this into three to four dosages each day.
There have been no studies conducted to determine whether or not SR9009 is effective when consumed orally.
SR9009 is a performance enhancer that may be purchased online and used for the sport of bodybuilding.
While some users claim that it increased their endurance, others claim that it has minimal or no advantages at all. Many people find that it is difficult to utilise because it is recommended that they take the medication three to four times each day.